179
Participants
Start Date
February 29, 2012
Primary Completion Date
April 30, 2017
Study Completion Date
April 30, 2017
Methotrexate
"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
Mt Sinai School of Medicine, New York
Penn State University, State College
University of Pennsylvania, Philadelphia
Metropolitan Gastroenterology Group, PC, Chevy Chase Clinical Research, Chevy Chase
University of Maryland, Baltimore
University of North Carolina, Chapel Hill
Charlotte Gastroenterology & Hepatology, Charlotte
Asheville Gastroenterology Associates, Asheville
Medical University of South Carolina, Charleston
Atlanta Gastroenterology, Atlanta
Shafran Gastroenterology, Winter Park
University of Louisville, Louisville
University of Kentucky, Lexington
Great Lakes Gastroenterology, Mentor
Case Western Reserve University, Cleveland
Indiana University IU Health, Indianapolis
Henry Ford Health System, Novi
University of Iowa, Iowa City
University of Wisconsin, Madison
Minnesota Gastroenterology, Plymouth
Mayo Clinic, Rochester
Northwestern University, Chicago
The University of Chicago, Chicago
Baylor University, Houston
University of Colorado, Denver
University of Utah, Salt Lake City
University of Southern California, Los Angeles
Harborview Medical Center, Seattle
University of Washington, Seattle
Massachusetts General Hospital, Boston
Dartmouth College, Lebanon
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of North Carolina, Chapel Hill
OTHER